Saltar al contenido
Merck
  • Reduction of lipid peroxidation products and advanced glycation end-product precursors by cyanobacterial aldo-keto reductase AKR3G1—a founding member of the AKR3G subfamily.

Reduction of lipid peroxidation products and advanced glycation end-product precursors by cyanobacterial aldo-keto reductase AKR3G1—a founding member of the AKR3G subfamily.

FASEB journal : official publication of the Federation of American Societies for Experimental Biology (2014-11-08)
Jan Hintzpeter, Hans-Joerg Martin, Edmund Maser
RESUMEN

The purpose of this study was to investigate the origin and function of the aldo-keto reductase (AKR) superfamily as enzymes involved in the detoxification of xenobiotics. We used the cyanobacterium Synechocystis sp. PCC 6803 as a model organism and sequence alignments to find bacterial AKRs with highest identity to human enzymes. Disappearance of NADPH was monitored spectrophotometrically to calculate enzymatic activity. The molecular weight of the native protein was determined by size exclusion chromatography. Substrate docking was performed by SwissDock. Sequence alignments identified the NADPH-dependent AKR3G1 having 41.5 and 40% identity with the human enzymes AKR1B1 and AKR1B10, respectively. Highest enzymatic efficiency was observed with 4-oxonon-2-enal (4-ONE; k(cat)/K(m), 561 s(-1) mM(-1)) and 4-hydroxynonenal (k(cat)/K(m), 26.5 s(-1) mM(-1)), respectively. P74308 is the most efficient enzyme for 4-ONE discovered until now. Cooperativity of this monomeric enzyme was observed with some substrates. Enzyme inactivation or oligomerization as possible explanations for nonhyperbolic enzyme kinetics were ruled out by Selwyn's test and gel filtration. The role of the little investigated carbonyl-reducing enzymes in detoxification seems to be in fact a very old process with rarely observed nonhyperbolic enzyme kinetics as an adaptation mechanism to higher concentrations of reactive oxygen species.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
5-(Hydroxymethyl)furfural, ≥99%, FG
Sigma-Aldrich
Indomethacin, 98.5-100.5% (in accordance with EP)
Sigma-Aldrich
5-Hydroxymethyl-2-furaldehyde, 99%
Sigma-Aldrich
Zimtaldehyd, natural, ≥95%, FG
Sigma-Aldrich
Hexanal, 98%
Sigma-Aldrich
Methylglyoxal solution, ~40% in H2O
Sigma-Aldrich
Coumarin, ≥99% (HPLC)
Sigma-Aldrich
trans-Cinnamaldehyde, 97%
Sigma-Aldrich
Butyraldehyde, ≥99.0%, dry
Sigma-Aldrich
4-Nitrobenzaldehyde, 98% (GC)
Sigma-Aldrich
DL-Glyceraldehyde, ≥90% (GC)
Sigma-Aldrich
Carbenicillin, Ready Made Solution, 100 mg/mL in ethanol/water, 0.2 μm filtered
Sigma-Aldrich
4-Pyridinecarboxaldehyde, 97%
Sigma-Aldrich
Glyoxal solution, 40 wt. % in H2O
Sigma-Aldrich
Glyoxal solution, for molecular biology, BioReagent, ~40% in H2O (~8.8 M)
Sigma-Aldrich
Furfural, 99%
Supelco
5-(Hydroxymethyl)furfural, analytical standard
Sigma-Aldrich
Furfural, ≥98%, FCC, FG
Sigma-Aldrich
Butyraldehyde, purified by redistillation, ≥99.5%
Sigma-Aldrich
trans-Cinnamaldehyde, ≥99%
Sigma-Aldrich
Crotonaldehyde, predominantly trans, ≥99%, contains 0.1-0.2% BHT as stabilizer, 1% H2O as stabilizer
Sigma-Aldrich
Crotonaldehído, mezcla de cis y trans, ratio of cis- and trans-isomers (~1:20), ≥99.5% (GC)
Sigma-Aldrich
trans-2-Hexen-1-al, 98%
Sigma-Aldrich
Butyraldehyde, ≥96.0%
Sigma-Aldrich
Indomethacin, meets USP testing specifications
Sigma-Aldrich
trans-Cinnamaldehyde, FCC, FG
Sigma-Aldrich
Furfural, natural, ≥98%, FCC, FG
Sigma-Aldrich
trans-2-Hexen-1-al, ≥95%, FCC, FG
Sigma-Aldrich
Pyruvaldehyde solution, 40 wt. % in H2O
Sigma-Aldrich
Hexanal, ≥97%, FCC, FG